Dermatology Summit 2023

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.

Mr. Bitterman was recently appointed Executive Chair and Principle Executive Officer of Phio Pharmaceuticals, Corp. in September of 2022 where he is responsible for all aspects of company operations. He served as Chairman of the Board of Phio since 2012. Previously Mr. Bitterman was CEO and Vice Chairman of the Board of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, Ltd. of Osaka Japan from 2005 until March of 2019. Prior to Cutanea Mr. Bitterman was President of Dermik Laboratories, a wholly owned subsidiary of Aventis Pharma from 1994 through 2004. His previous experience also includes senior positions of financial responsibility and Investor relations in Rhone Poulenc Rorer. He is a graduate of Boston University Graduate School of Management and College of the Holy Cross.

Mr. Bourdon joined LEO Pharma A/S as CEO in April 2022 coming from a similar position at Orphazyme A/S. During his 25 years in the pharmaceutical industry across 3 continents, Bourdon’s focus has been to build strong and diverse teams, while fostering an environment focused on innovation and curiosity with one constant driver in mind: Making a meaningful difference for patients.

Earlier in his career, Bourdon held a series of leadership roles at Amgen, including Senior Vice President and General Manager for the U.S. Oncology Business, with ten marketed portfolios comprising one of the company’s largest businesses. During his tenure in the US, Bourdon helped launching 3 oncology products, managed to launch 2 biosimilars, and accelerated Amgen’s pipeline focus on new innovative cancer medicine.

Earlier, Bourdon was Vice President and General Manager for Amgen, Germany. He also worked at Alexion as Senior Vice President, EMEAC, leading the commercial development of ultra-orphan therapies across 40 countries.

He earned his MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland, and a BA from the Institut Superieur de Gestion, Paris, France.

French-German citizen, he has worked and lived in more than 6 countries, incl. Japan, Germany, France, Switzerland, and US. He is now living in Denmark with his husband.

Dr. Brubaker is a recognized pharmaceutical drug and medical device development expert with 25+ years of experience with an emphasis in ophthalmic, otic, and respiratory disease areas. He has demonstrated sustained high performance throughout his career. Progressing from scientific/technical subject matter expert to technical and project management/leadership, strategic franchise leadership, project and portfolio management, and R&D executive leadership roles to current roles of global program leadership of drug development and medical device global development teams, he is a proven leader with ever increasing accountabilities and responsibilities.

Prior to joining Xequel, Michael worked at Abbott Laboratories, Bausch & Lomb Pharmaceuticals, and Alcon Laboratories, where he held various positions within pharmaceutical clinical research, pharmaceutical project strategic leadership working in numerous ophthalmology disease areas and as the VP of enterprise-wide project/program management. Most recently, Michael worked at Novartis Pharmaceutical Corp., as a Global Program Head in Ophthalmology Development Unit, and was responsible for setting the ophthalmic digital SaMD development strategy and leading the Xiidra & Ophtha digital global program teams. Michael earned his Ph.D. in Bio-organic Chemistry from Wichita State University in Wichita, Kansas, and he was a post-doctoral fellow at University of California – Molecular & Cell Biology Department.

Dr. Cameron is an Assistant Professor in the Department of Dermatology at Mount Sinai in New York. He is a board-certified dermatologist with expertise in drug development and inflammatory skin diseases with previous experience in the pharmaceutical industry and healthcare consulting. He is a consultant for various biotech and pharmaceutical companies. He completed his residency training at MSKCC and the University of Colorado. Prior to residency training, he received his undergraduate degree from Duke University and his medical degree from the University of South Florida.

Previously a medical director at Pfizer, he has expertise in the treatment of eczema, psoriasis, alopecia areata and other types of hair loss, vitiligo, acne, and skin cancer, as well as in performing various cosmetic treatments including botox, fillers, lasers, microneedling, PRP, and chemical peels. He is co-author of more than 20 publications in peer-reviewed medical journals and 2 dermatology textbook chapters.

Matt Davidson PhD is cofounder and CEO of Azora Therapeutics, a company developing best-in-class aryl hydrocarbon receptor agonists (AhR) for serious diseases. Prior to founding Azora, Dr. Davidson founded and ran Verrica Pharmaceuticals (Nasdaq: VRCA) a dermatology focused pharmaceutical company developing therapies for common skin diseases after a personal experience with a wart on his finger that would not respond to treatment. Dr. Davidson ran Verrica as CEO and chairman of the board from inception until the decision to go public, leading the company from preclinical into successful pivotal P3 clinical trials raising over $100M in the process.

After graduating from UC Berkeley with high distinction in molecular and cellular biology, Dr. Davidson earned his PhD in Immunology from the Stanford University School of Medicine. Dr. Davidson is the inventor of 6 issued patents and author of numerous scientific publications in high impact journals such as JAMA Dermatology, Nature and the Lancet. He is the recipient of the 2019 Biocom Catalyst Award for life science trailblazers.

As Managing Partner at Olive Tree Capital, Nichola leads stage and sector agnostic equity investments, primarily in technology and life sciences companies. Nichola led his first technology startup company through acquisition, and currently serves on the multiple boards, including Alto Pharmacy (the leading digital pharmacy in the USA) and DermBiont (developing targeted topical therapeutics to treat skin diseases), where he is also a co-founder and Chief Business Officer.

Dr. Irina Erenburg is the President & CEO of AVAVA, Inc – a company dedicated to developing breakthrough aesthetic products for treatment of all skin tones and types. AVAVA was created from Blossom Innovations, LLC – a discovery and development company that Dr. Erenburg continues to lead since co-founding it in 2011. Dr. Erenburg is a serial entrepreneur, with extensive experience in innovation business leadership. She is the co-founder and board member of R2 Technology and Soltego, Inc and has recently joined the Board of Directors of Sientra, a publicly traded company in the field of breast augmentation and reconstruction. Prior to her role at Blossom and AVAVA, she was the Director of Strategic Transactions at the Partners HealthCare Office of Innovations, Boston’s largest hospital network and a teaching affiliate of Harvard University. There, she was responsible for execution and management of high-value deals and launch of several successful start-ups, including Zeltiq Aesthetics. Dr. Erenburg holds a Ph.D. in Biomedical Science from the Mount Sinai School of Medicine in NY.

Dr. Gelber is an executive with over 25 years of experience in discovery and drug development of immune therapeutics and diagnostics. Dr. Gelber has held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation).

Prior to founding Serpin Pharma, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC and supervised a large group of translational research scientists. Dr. Gelber’s group during her tenure at ATCC was awarded ~ $500MM in grants and contracts. Prior to ATCC, Dr. Gelber served as the VP of R&D for MannKind Corp (MNKD) and supervised nonclinical research & safety support to MNKD’s clinical trials for Afrezza. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University. She has published numerous scientific manuscripts and textbook chapters and is the inventor of 28 granted patents and 72 patent applications.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & Autoimmunity. Under his leadership, revenue has increased by nearly 600% which includes the addition of five new sources of potential revenue. With a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. He began his career at Novartis in 2003 as Chief Commercial Officer and later became President in 2010. Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Ms. Van Hove is a global commercial leader with over 20 years of diverse experience in the pharmaceutical, consumer and medical device industry. Her experience spans North America to Europe, Africa, the Middle East to Asia Pacific and Latin America. Ms. Van Hove is currently President and CEO of Revelle Aesthetics, a venture-backed, medical aesthetics company, and previously held several commercial leadership roles at both start-up and large-cap companies.

Ms. Van Hove also serves as Executive Chair on the Board of Directors of Sientra, a publicly traded medical aesthetics company specialized in breast aesthetics. And she is a proud member of the Board of Directors of Mission Plasticos, a global non-profit dedicated to providing reconstructive surgery to children in need.

Ms. Van Hove previously served as Chief Commercial Officer of Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies in immunology and inflammation. Prior to Sienna, Ms. Van Hove was Senior Vice President of International Strategic Marketing at Allergan, where she oversaw commercial operations for the medical aesthetics, eye care and specialty care franchises. Previously, Ms. Van Hove managed sales & marketing, customer service and customer excellence in Europe, Africa and the Middle East and led Allergan’s international medical aesthetics operations.

Ms. Van Hove is a proud mom of three little girls and wife to a firefighter, residing with her family in Nashville, TN.

Vijay Iyengar joined Incyte as Executive Vice President, Global Strategy and Corporate Development in 2016. In 2022, his role was expanded to EVP, Head of Global Medical Affairs, Product and Partnership Strategy. In this role, he leads the Global Product Strategy, Value, Access and Pricing, Business Development, Alliance Management, ROW Partnerships, and Global Medical Affairs teams. Dr. Iyengar has more than 20 years of pharmaceutical industry experience. Previously, he served as the President of Genoptix Corporation, a Novartis Company, where he led a 650-person organization that offered CAP/CLIA-certified oncology diagnostic testing and clinical trial assay development and execution services. Prior to that, Dr. Iyengar held leadership roles in both U.S. and Global functions at Novartis, as Vice President and Rare Diseases Franchise Head at Novartis Oncology and Oncology General Manager of Novartis Greece. Before joining Novartis, he was an Engagement Manager at McKinsey & Company where he served pharmaceutical and medical device clients as part of their healthcare practice. Dr. Iyengar received his Bachelor of Science in Biology from Stanford University and his M.D. from Harvard Medical School.

Since January 2021, Dr. Kim Kjoeller has served as the CEO at UNION therapeutics. He brings more than 20 years of experience from various executive positions in the pharmaceutical industry of which the last 12 years is within dermatology. Before joining UNION, Dr. Kjoeller held positions at Sanofi, Lundbeck, Sanofi Pasteur MSD and LEO Pharma across R&D, commercial and general management. From 2015 until 2021, Dr. Kjoeller served as Executive Vice President R&D at LEO Pharma.

After graduating from the Copenhagen Medical Faculty in 1994, Dr. Kjoeller held several positions at Copenhagen University Hospital in medicine and surgery until joining Danish Cancer Society, Institute for Epidemiologic Cancer Research in 1996. Dr. Kjoeller is the chairman of the Danish Life Science Cluster, an organization established to foster collaboration between academia, business, communities and regions to jointly progress innovation and improve health care delivery in Denmark.

Dr. Kjoeller is author/co-author of 35+ scientific publications, and has given lectures at Scientific Meetings in Denmark and the Nordics as well as at Pharma Industry Meetings in Europe and the US.

Todd Krueger is the Chief Executive Officer, President and a Director of AOBiome Therapeutics. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Phi Beta Kappa from Northwestern University with a Bachelor of Economics and earned his MBA from the Kellogg School of Management.

Mr. Krueger has over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform.

Mr. Krueger is also on the Board of Directors at Neofluidics, a manufacturer of instrumentation for lipid nanoparticles, Tenza, a spinout of George Church’s lab focused on delivering drugs to mucosal surfaces using proprietary bacterial secretion technology, and Isolation Bio, a microbiome tools company based in the United States.

Jesper J. Lange holds a Master of Law (LLM) degree from Columbia University Law School in New York and is co-founder of MC2 Therapeutics. He joined the company from his position as M&A partner in a major Danish law firm.

Based on his leadership and strong entrepreneurial skills Jesper is focused on bringing together the expertise of people and companies through a fundamental belief in inclusion and diversity as the main driver of passion, innovation and high performance.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Ketan Patel is a Partner with F-Prime Capital and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime Capital in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.

Dr. Patel focuses on investing in therapeutics and medical device companies and has served on the Board of Directors of ABK Biomedical, Aclaris Therapeutics (NASDAQ:ACRS), Avalyn Pharma, Caplin Steriles, Comanche Biopharma, Eywa Pharma, Ivenix (acquired by Fresenius Kabi), Laurus Labs (NSE:LAURUSLABS), Medwell Ventures, Menlo Therapeutics (NASDAQ:MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio (NASDAQ:RLYB), and Vicept Therapeutics (acquired by Allergan).

Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his MD and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.

Dr. Dale Raine joined Lazard in January 2016 as a Managing Director and Co-Head of European Healthcare Investment Banking. He advises healthcare clients on strategic advisory and capital markets transactions globally. Previously, he spent over 10 years at Deutsche Bank based in London and New York.

Prior to Investment Banking, Dr. Raine was a postdoctoral research scientist in the Division of Molecular and Cellular Biology at Imperial College London and a visiting scientist in the Department of Chemistry at The Scripps Research Institute. Dale co-founded the International Malaria Proteome Consortium and contributed to the Malaria Genome Project.

Dr Raine is a graduate of Imperial College London where he received his bachelor’s degree in Biochemistry, Master’s degree in Infection and Immunology and Ph.D. in Malaria Cell Biology. Dr Raine is an Associate of the Royal College of Science.

Dale lives in London with his wife, three children and loving Labrador.

Jason Richey has over 25 years of experience in the medical device industry and joined Cytrellis Biosystems in June of 2022 as President & CEO. Cytrellis is a medical aesthetic device company (Woburn, MA) that worked together with MGH & Harvard to develop and manufacture a new a novel approach to treating skin laxity with the ellacor dermal micro-coring system. Ellacor is an FDA approved device, that removes excess skin by taking thousands of micro cores, less than .5mm in size, through a minimally invasive approach that is performed in an office-based, out-patient setting. Prior to joining Cytrellis, Jason served as President and Chief Operating Officer for Cutera, Inc. (NASDAQ: CUTR), a leading global manufacturer of energy-based aesthetic devices. Previously, Jason served a dual executive role as President of North America & President of the Neuromodulation Franchise for LivaNova, PLC (NASDAQ: LIVN), a $3 billion global medical device manufacturer with a presence in more than 100 countries worldwide. He joined LivaNova from Cyberonics, Inc. where he served as Global Vice President of Sales, Marketing, & Market Access among many other roles. In every leadership role he has held, Jason has driven innovation, substantial top-line growth & profitability to the corporation. Jason began his medical device career at B Braun Medical and holds a Bachelor of Arts degree in Biology from Indiana University.

Ethan has 15 years of investing experience. He invested more than $900M in companies with a combined enterprise value of greater than $5B. Prior to founding Gore Range, Ethan Co-Founded NYBX, Inc. (LedgerX Holdings) serving as CFO. Ethan’s experience with fundraising through traditional venture capital avenues helped inspire his philosophy for Gore Range’s personal approach.

Ethan serves as a board member and advisor to DermX Media Group. For a decade Ethan has overseen the expansion of DermX’s offerings and the institutionalization of relationships with key dermatology industry partners. At Gore Range, Ethan serves on the boards of CoreMedica, Novaestiq, Or-Genix, Ornovi, Platform Imaging, and xMD. He is an observer on Dorsata and Novascan.

Ethan has two degrees from the MIT (B.S. in Economics & B.S. in Management Science) and a MBA from the Fuqua School of Business at Duke University.

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Dr. Waldman is CEO and Cofounder of VeraDermics, Inc. a medical dermatology company focused on the development of innovative therapeutics that transform the standard-of-care across a broad range of common skin conditions. Dr. Waldman is a board-certified dermatologist by training. He received his Medical Doctorate from the University of Missouri-Kansas City and completed his residency in dermatology at the University of Connecticut. Since 2017, he has authored more than 100 peer-reviewed journal articles, abstracts, posters, and academic meeting presentations. Under his tutelage, VeraDermics Inc. has advanced the development of four dermatology-focused pharmaceuticals and raised more than $22M in equity financing.

Qiang (John) Wang has been an Associate Vice President and Head of Immunology External Innovation at Eli Lilly since December 2018. Since joining Eli Lilly, John has identified and brought in numerous external innovation opportunities leading to several significant transactions including a $1.1 billion acquisition of Dermira in 2020, which internalized a Phase 3 program (Lebrikizumab) for the treatment of atopic dermatitis. Prior to joining Lilly, John worked at Merck Business Development and Licensing group and Sanofi External Innovation team. While being appointed as an Adjunct Assistant Professor at University of Pennsylvania School of Veterinary Medicine, John started his industry career as a Principal Research Scientist at Wyeth Research (Pfizer) Neuroscience, CVMD and Women’s Heath. John obtained a Veterinarian Degree from Qingdao Agricultural University College of Animal Science & Veterinary Medicine, China and a PhD in Pharmacology from University of London, St George’s Hospital Medical School, UK and conducted his postdoctoral training at both Harvard Medical School and Boston University.

Nick is a Partner at Medicxi and is a Board Director of Vaderis, Versanis, Alderaan Biotechnology and Yukin Therapeutics. Prior to joining Medicxi, Nick co-founded a start-up urology company and worked in various business development and consulting roles for biotechnology companies.

Nick graduated with an MPharm from Cardiff University and completed his training at St George’s Hospital, London before returning to Cardiff to receive his PhD in urological drug delivery.

Dr. Xu is a physician-engineer, board certified dermatologist, academic, and entrepreneur. He holds an appointment as the Director of Medical Research at the Querrey Simpson Institute for Bioelectronics at Northwestern University, and the Ruth K. Freinkel, MD, Professorship in the Department of Dermatology at Northwestern University. Dr. Xu has authored more than 120 peer-reviewed publications, which include works in Nature, Science, The New England Journal of Medicine, and the Proceedings of the National Academy of Sciences. Furthermore, he is an inventor on 15 pending and granted patents in the fields of digital health, medical device development, and medical innovation as an MIT 35 Under 35 honoree (Class of 2022). He is currently on leave from his academic position at Northwestern University to serve as the CEO of Sibel Health where he is also a cofounder and board member. To date, Sibel has raised more than $50 million USDs, launched ICU-grade wearable sensors in more than 20 countries, and monitored more than 12,000 individuals with a focus on maternal and neonatal health.

George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, has built Regeneron for nearly 35 years alongside President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D. Regeneron invents life-transforming medicines for people with serious diseases. Its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, all of which were homegrown in its laboratories, for a range of diseases, including cancer, vision-threatening eye diseases, asthma and infectious diseases. Dr. Yancopoulos is the holder of more than 100 patents and a principal inventor of Regeneron’s medicines and foundational technologies. He is the key driver of Regeneron’s unique science-driven culture and successful drug discovery and development engine, which encompasses industry leading antibody technologies as well as a diverse set of genetics medicine approaches.

After graduating as valedictorian at Bronx High and Columbia University, Dr. Yancopoulos received his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. Later at Columbia, he served as legendary geneticist Dr. Fred Alt’s first post-doctorate student, working in molecular immunology. During his career, Dr. Yancopoulos has been the 11th most highly cited scientist in the world, was elected to both the National Academy of Sciences and the American Academy of Sciences and was elected as a Fellow by the American Association for the Advancement of Science (AAAS). In 2019, Dr. Yancopoulos was awarded Columbia College’s Alexander Hamilton Medal, the highest honor awarded to a member of the Columbia College community for distinguished service and accomplishment in any field of endeavor. In recognition of Regeneron’s work in developing a COVID-19 treatment, Dr. Yancopoulos was named on Fortune’s World’s 25 Greatest Leaders: Heroes of the Pandemic and received the Prix Galien Roy Vagelos Pro Bono Humanum Award for Global Health Equity and Business Council of Westchester’s Global Leadership Laureate Award along with Dr. Schleifer.

Karl currently serves as Chief Scientific Officer (CSO) and Head of R&D at Almirall, a global biopharmaceutical company focused on skin health based in Barcelona, Spain. He has three decades of leadership experience in drug discovery and early development gained in positions of increasing responsibility in international markets such as Germany, Japan, and the United States.

Before joining Almirall, Karl developed most of his career at Bayer Pharmaceuticals, holding Senior Vice President roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives, and immunology/inflammation.

Karl holds a PhD in Biochemistry from the University of Tübingen (Germany) and he has co-authored more than 50 scientific publications covering basic research as well as drug discovery topics.

Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.

Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Slaoui has served as Chief Corporate Development Officer at Galderma since September 2020. Previously she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. Since joining GSK’s Business Development teams in 2006, she has held various roles of increasing seniority and has executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is currently the Medical Director of Kira Pharmaceuticals, a Boston-based global biotech company developing innovative complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she serves as Chief Strategy Officer. As an Instructor in Dermatology at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital (MGH), she specializes in melanoma and pigmentary disorders.

Christina attended the California Institute of Technology, where she received her bachelor’s degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a medical fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral research was at the Cutaneous Biology Research Center of MGH.

Christina’s bench research has focused on melanocyte biology and mechanisms leading to pigment dysregulation, with an emphasis on clinically translatable opportunities in pigmentary disorders and melanoma. Her work additionally explores strategies for cutaneous drug delivery. Christina’s clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research support and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health.